Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samer Al Hadidi

Showing results (51-60 of 94) with videos related to

Pageof 10
Sort By:
Blood Advances|March 1, 2023
Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysisFarah Mazahreh, Liyan Mazahreh, Carolina Schinke, et al.
Ejhaem|May 19, 2023
Variability of definition of high-risk multiple myeloma across phase III clinical trialsFaris Jamal Abu Za'nouneh, Obada Ababneh, Carolina Schinke, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 5, 2026
Choosing Wisely in First Relapse of Multiple Myeloma: Expert Insights on Treatment SelectionSamer Al Hadidi, Caitlin Costello, Luciano J Costa, et al.
Clinical Hematology International|October 13, 2025
Treatment Outcomes of Multiple Myeloma in Developing Countries: A Systematic Review and Meta-AnalysisJehad Almasri, Bashar Hasan, Zin Tarakji, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2024
Reflections and Roadmaps: Career Development beyond the FDA-AACR Oncology Educational FellowshipTimil Patel, Chris Chen, Samer Al Hadidi, et al.
JCO Global Oncology|August 12, 2022
Global Myeloma Trial Participation and Drug Access in the Era of Novel TherapiesRaleigh Ayoolu Fatoki, Kelly Koehn, Amar Kelkar, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 2, 2024
Treatment Pattern, Healthcare Resource Utilization and Symptom Burden Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort StudyHira Mian, Hsien Seow, Gregory R Pond, et al.
Leukemia & Lymphoma|July 19, 2021
Health disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: a population-based studySamer Al Hadidi, Deepa Dongarwar, Hamisu M Salihu, et al.
Haematologica|September 4, 2025
The invisible divide: the impact of racial and geographic disparities on multiple myeloma outcomes - insights from a single-site studyMichael A Bauer, Phillip Farmer, Joseph L Su, et al.
British Journal of Haematology|December 10, 2022
Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysisTommy Etekal, Kelly Koehn, Douglas W Sborov, et al.
Pageof 10

Showing results (51-60 of 94) with videos related to

Sort By:
Pageof 10
Blood Advances|March 1, 2023
Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysisFarah Mazahreh, Liyan Mazahreh, Carolina Schinke, et al.
Ejhaem|May 19, 2023
Variability of definition of high-risk multiple myeloma across phase III clinical trialsFaris Jamal Abu Za'nouneh, Obada Ababneh, Carolina Schinke, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 5, 2026
Choosing Wisely in First Relapse of Multiple Myeloma: Expert Insights on Treatment SelectionSamer Al Hadidi, Caitlin Costello, Luciano J Costa, et al.
Clinical Hematology International|October 13, 2025
Treatment Outcomes of Multiple Myeloma in Developing Countries: A Systematic Review and Meta-AnalysisJehad Almasri, Bashar Hasan, Zin Tarakji, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2024
Reflections and Roadmaps: Career Development beyond the FDA-AACR Oncology Educational FellowshipTimil Patel, Chris Chen, Samer Al Hadidi, et al.
JCO Global Oncology|August 12, 2022
Global Myeloma Trial Participation and Drug Access in the Era of Novel TherapiesRaleigh Ayoolu Fatoki, Kelly Koehn, Amar Kelkar, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 2, 2024
Treatment Pattern, Healthcare Resource Utilization and Symptom Burden Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort StudyHira Mian, Hsien Seow, Gregory R Pond, et al.
Leukemia & Lymphoma|July 19, 2021
Health disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: a population-based studySamer Al Hadidi, Deepa Dongarwar, Hamisu M Salihu, et al.
Haematologica|September 4, 2025
The invisible divide: the impact of racial and geographic disparities on multiple myeloma outcomes - insights from a single-site studyMichael A Bauer, Phillip Farmer, Joseph L Su, et al.
British Journal of Haematology|December 10, 2022
Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysisTommy Etekal, Kelly Koehn, Douglas W Sborov, et al.
Pageof 10